Clinical Trial

Immune Checkpoint Inhibitors (ICIs) Retreatment in Second-line Treatment of Advanced Gastric Cancer: a Retrospective, Real-world Study

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 7, 2025 (before its estimated May 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a single-center, retrospective, observational, real-world study. We collected general and clinical data of patients with advanced gastric cancer who were admitted to the First Affiliated Hospital of Zhengzhou University from January 2018 to July 2024.
Trial Details
NCT Number NCT06814548
Lead Sponsor Yongxu Jia
Conditions Gastric Cancer, Gastroesophageal Junction Cancer, Immune Checkpoint Inhibitors (ICIs), Second-line, Retreatment
Enrollment 200 participants
Start Date 2025-02-10
Primary Completion 2025-05-31 (estimated)
Study Completion 2025-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-07